Exhibit 99.1

Bruker BioSciences Reports Solid Revenue Growth and Improved
Earnings in Second Quarter 2006

Billerica, Massachusetts, August 1, 2006 (BUSINESS WIRE)  —  Bruker BioSciences Corporation (NASDAQ: BRKR) today reported second quarter 2006 results.  On July 1, 2006, Bruker BioSciences completed its acquisition of Bruker Optics Inc.  Due to the Laukien family majority ownership of both companies, this acquisition is required to be accounted for as a pooling of interests.  As a result of this accounting treatment, all historical periods will be restated beginning in the third quarter of 2006 as if the companies had been combined.  Presented below first are the results of operations for Bruker BioSciences excluding the results of Bruker Optics for the three and six months ended June 30, 2006 and 2005, as will be reported in the Company’s second quarter 2006 Form 10-Q.

Also presented below are combined results of operations, which present the Bruker BioSciences results described above combined with the results of Bruker Optics for the three and six months ended June 30, 2006 and 2005.  These combined historical financial statements will be presented in a footnote to the Company’s second quarter 2006 Form 10-Q, and in future 10-Q filings as the combined historical financial statements of Bruker BioSciences. They do not contain any pro forma adjustments, as was required for the Company’s Proxy Statement dated May 26, 2006.

Bruker BioSciences Results of Operations, Excluding Bruker Optics:

For the second quarter of 2006, revenue increased by 9.0% to $77.8 million, compared to revenue of $71.4 million in the second quarter of 2005.  Excluding the effects of unfavorable foreign currency translation, second quarter 2006 revenue increased by 9.6% year-over-year.  For the six months ended June 30, 2006, revenue increased 4.2% to $152.3 million, compared to $146.3 million for the same period last year.  Excluding the effects of unfavorable foreign currency translation, revenue for the six months ended June 30, 2006 increased by 8.3% year-over-year.

GAAP net income in the second quarter of 2006 was $0.5 million, or $0.01 per diluted share, compared to GAAP net income of $0.3 million, or $0.00 per diluted share, in the second quarter of 2005.  Included in second quarter 2006 GAAP net income were $0.2 million of stock-based compensation expense and $1.2 million of acquisition related charges, net of tax.  Excluding the acquisition related charges associated with the acquisition of Bruker Optics, second quarter 2006 non-GAAP net income was $1.7 million, or $0.02 per diluted share.

GAAP net income for the six months ended June 30, 2006 was $1.3 million, or $0.01 per diluted share, compared to GAAP net income of $0.7 million, or $0.01 per diluted share, during the six months ended June 30, 2005.  Included in GAAP net income for the six months ended June 30, 2006 were $0.4 million of stock-based compensation expense and $2.4 million of acquisition related charges, net of tax.  Excluding the acquisition related

charges, non-GAAP net income for the six months ended June 30, 2006 was $3.6 million, or $0.04 per diluted share.

Bruker BioSciences Combined Results of Operations, Including Bruker Optics:

For the second quarter of 2006, combined revenue increased by 12.1% to $100.5 million, compared to combined revenue of $89.3 million in the second quarter of 2005.  Excluding the effects of unfavorable foreign currency translation, second quarter 2006 combined revenue increased by 12.7% year-over-year.  For the six months ended June 30, 2006, combined revenue increased by 8.5% to $195.3 million, compared to $179.7 million for the same period last year.  Excluding the effects of unfavorable foreign currency translation, combined revenue for the six months ended June 30, 2006 increased by 12.7% year-over-year.

Combined GAAP net income in the second quarter of 2006 was $2.5 million, or $0.02 per diluted share, compared to combined GAAP net income of $1.4 million, or $0.01 per diluted share, in the second quarter of 2005.  Included in second quarter 2006 combined GAAP net income were $0.2 million of stock-based compensation expense and $2.8 million of acquisition related charges, net of tax.  Excluding the acquisition related charges, second quarter 2006 combined non-GAAP net income was $5.3 million, or $0.05 per diluted share.

Combined GAAP net income for the six months ended June 30, 2006 was $5.8 million, or $0.06 per diluted share, compared to combined GAAP net income of $2.7 million, or $0.03 per diluted share, for the six months ended June 30, 2005.  Included in combined GAAP net income for the six months ended June 30, 2006 were $0.4 million of stock-based compensation expense and $4.0 million of acquisition related charges, net of tax.  Excluding the acquisition related charges, combined non-GAAP net income for the six months ended June 30, 2006 was $9.8 million, or $0.10 per diluted share.

Comments and Analysis

Commenting on the financial results, Frank Laukien, President and CEO, said: “During the second quarter and first six months of 2006 we have experienced solid increases in revenue and also significantly improved profitability.  Excluding acquisition related charges and excluding Bruker Optics, our net income for the first six months of 2006 has increased five-fold.  Also still excluding Bruker Optics, our currency-adjusted revenue growth rate has accelerated from 7.1% in the first quarter 2006 to 9.6% in the second quarter 2006. Including Bruker Optics, our combined adjusted EBITDA reached $21.5 million for the first six months of 2006, and $46.1 million for the last twelve months ended June 30, 2006.”

William Knight, Chief Financial Officer, commented: “I am very pleased that our combined financial results, including Bruker Optics but excluding acquisition related charges, show further improved financial performance for the first six months of 2006, including currency-adjusted revenue growth of 12.7% year-over-year, increasing gross

profit margins of 46%, a decreasing effective tax rate of 43% and significantly increased combined earnings per share.  We are optimistic that for the remainder of 2006 our traditional core businesses, as well as the additional life-science and industrial market segments that we have entered via our recent acquisitions, will enable us to continue above industry-average top-line growth, as well as further improvements in combined profitability compared to 2005.”

USE OF NON-GAAP FINANCIAL MEASURES

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP measure of Adjusted EBITDA.  Adjusted EBITDA is defined as US GAAP operating income (loss) excluding depreciation and amortization expense, the write-down of demonstration equipment to net realizable value and acquisition related charges.  We believe that the inclusion of this non-GAAP measure helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such results to previous periods or forecasts.  However, the non-GAAP financial measure included in this press release is not meant to be a better presentation or a substitute for results of operations prepared in accordance with GAAP.  Reconciliations of this non-GAAP financial measure to the most directly comparable GAAP financial measures are set forth in the accompanying tables.

EARNINGS CONFERENCE CALL

Bruker BioSciences will host an operator-assisted earnings conference call at 9 a.m. Eastern Time on Wednesday, August 2, 2006.  To listen to the webcast, investors can go to www.bruker-biosciences.com and click on the live web broadcast symbol.  The webcast will be available through the Company web site for 30 days.  Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada.  Investors should refer to the Bruker BioSciences Quarterly Earnings Call.  A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 91585873.

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc.  Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools.  Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of chemical, biological, radiological and nuclear (CBRN) detection products for homeland security.  Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular

spectroscopy technology.  For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company’s products, exposure to currency fluctuations, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2005, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K.  We disclaim any intent or obligation to update these forward-looking statements.

Condensed consolidated statements of operations, operating business information, and balance sheets follow for Bruker BioSciences Corporation.

Bruker BioSciences Corporation
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS,
EXCLUDING BRUKER OPTICS (in thousands, except per share data)

	Three Months Ended June 30,				Six Months Ended June 30,
	2006		2005		2006		2005
Product revenue	$	67,373	$	60,723	$	132,330	$	127,547
Service revenue	10,234		9,977		19,043		17,732
Other revenue	233		668		877		1,000
Total revenue	77,840		71,368		152,250		146,279
Cost of product revenue	38,599		34,275		74,841		72,540
Cost of service revenue	5,279		6,548		10,500		11,815
Total cost of revenue	43,878		40,823		85,341		84,355
Gross profit margin	33,962		30,545		66,909		61,924
Operating Expenses:
Sales and marketing	15,426		13,385		29,398		25,537
General and administrative	5,532		5,287		11,148		10,955
Research and development	10,619		10,962		20,993		21,982
Acquisition related charges	1,192		—		2,368		—
Total operating expenses	32,769		29,634		63,907		58,474
Operating income	1,193		911		3,002		3,450
Interest and other income (expense), net	459		554		1,122		424
Income before income tax provision and minority interest in consolidated subsidiaries	1,652		1,465		4,124		3,874
Income tax provision	1,127		1,145		2,775		3,070
Income before minority interest in consolidated subsidiaries	525		320		1,349		804
Minority interest in consolidated subsidiaries	45		36		93		103
Net income	$	480	$	284	$	1,256	$	701
Net income per share:
Basic	$	0.01	$	0.00	$	0.01	$	0.01
Diluted	$	0.01	$	0.00	$	0.01	$	0.01
Weighted average shares outstanding:
Basic	90,080		89,472		90,054		89,471
Diluted	90,493		89,599		90,403		89,591

Bruker BioSciences Corporation
COMBINED CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS, INCLUDING BRUKER OPTICS (in thousands, except per share data)

	Three Months Ended June 30,					Six Months Ended June 30,
	2006		2005			2006		2005
Product revenue	$	88,381	$	76,756		$	172,222	$	158,018
Service revenue	11,853		11,829			22,224		20,563
Other revenue	249		731			893		1,096
Total revenue	100,483		89,316			195,339		179,677
Cost of product revenue	47,850		41,327			92,562		86,405
Cost of service revenue	6,433		7,785			12,820		13,522
Total cost of revenue	54,283		49,112			105,382		99,927
Gross profit margin	46,200		40,204			89,957		79,750
Operating Expenses:
Sales and marketing	20,900		17,999			39,732		34,576
General and administrative	6,473		6,120			13,080		12,504
Research and development	12,285		12,486			24,560		25,025
Acquisition related charges	3,692		—			4,868		—
Total operating expenses	43,350		36,605			82,240		72,105
Operating income	2,850		3,599			7,717		7,645
Interest and other income (expense), net	2,333		(355		)	4,014		(495		)
Income before income tax provision and minority interest in consolidated subsidiaries	5,183		3,244			11,731		7,150
Income tax provision	2,614		1,845			5,854		4,372
Income before minority interest in consolidated subsidiaries	2,569		1,399			5,877		2,778
Minority interest in consolidated subsidiaries	45		35			93		103
Net income	$	2,524	$	1,364		$	5,784	$	2,675
Net income per share:
Basic	$	0.02	$	0.01		$	0.06	$	0.03
Diluted	$	0.02	$	0.01		$	0.06	$	0.03
Weighted average shares outstanding:
Basic	101,456		100,847			101,430		100,847
Diluted	101,869		100,974			101,779		100,966

Bruker BioSciences Corporation
SELECTED BUSINESS INFORMATION, EXCLUDING BRUKER OPTICS
(in thousands)

	Three Months Ended June 30,				Six Months Ended June 30,
	2006		2005		2006		2005
Total revenue	$	77,840	$	71,368	$	152,250	$	146,279
Operating income	$	1,193	$	911	$	3,002	$	3,450
Depreciation and amortization	1,789		2,583		3,914		4,852
Write-down of demonstration equipment	1,702		1,904		3,208		3,628
Acquisition related charges	1,192		—		2,368		—
Adjusted EBITDA	$	5,876	$	5,398	$	12,492	$	11,930

Bruker BioSciences Corporation
SELECTED BUSINESS INFORMATION, INCLUDING BRUKER OPTICS
(in thousands)

	Three Months Ended June 30,				Six Months Ended June 30,
	2006		2005		2006		2005
Total revenue	$	100,483	$	89,316	$	195,339	$	179,677
Operating income	$	2,850	$	3,599	$	7,717	$	7,645
Depreciation and amortization	2,581		3,283		5,075		5,852
Write-down of demonstration equipment	2,002		2,205		3,808		4,228
Acquisition related charges	3,692		—		4,868		—
Adjusted EBITDA	$	11,125	$	9,087	$	21,468	$	17,725

Bruker BioSciences Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS, EXCLUDING BRUKER
OPTICS (in thousands)

	June 30,		December 31,
	2006		2005
	(unaudited)
ASSETS
Current assets:
Cash and short-term investments	$	96,596	$	99,578
Accounts receivable, net	61,709		53,744
Due from affiliated companies	2,678		4,860
Inventories	103,174		96,333
Other current assets	11,879		11,094
Total current assets	276,036		265,609
Property and equipment, net	74,864		72,336
Intangible and other assets	28,826		22,942
Total assets	$	379,726	$	360,887
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	9,613	$	8,002
Accounts payable	12,340		14,118
Due to affiliated companies	3,472		3,857
Other current liabilities	90,965		85,551
Total current liabilities	116,390		111,528
Long-term debt	21,969		21,423
Other long-term liabilities	22,969		19,901
Minority interest in subsidiaries	324		233
Total shareholders’ equity	218,074		207,802
Total liabilities and shareholders’ equity	$	379,726	$	360,887

FOR FURTHER INFORMATION:	Michael Willett, Investor Relations Officer
	Tel: (978) 663-3660, ext. 1411
	Email: ir@bruker-biosciences.com